Canaccord lowered the firm’s price target on Ocuphire Pharma to $18 from $22 and keeps a Buy rating on the shares. The firm said Ocuphire expects an update from FDA on the APX3330 SPA in diabetic retinopathy, which should de-risk trial execution.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCUP:
- Ocuphire Pharma Gambles on Cash-Pay Strategy for RYZUMVI: Is It a Path to Profit or a Financial Pitfall?
- Ocuphire Pharma Shares Updates in Upcoming Investor Meetings
- Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update
- Ocuphire Pharma reports Q1 EPS (29c), consensus (13c)
- Ocuphire Pharma announces presentation on APX3330 at ARVO 2024